InvestSMART

Artrya Limited (ASX:AYA)

ALERT: Price-sensitive ASX Announcement for AYA
Current share price for AYA : $5.360 2.07 (62.92%)+
Announcement
Release
25 Feb 2026 7:58PM
Price at Release
$3.290
Full Release
download
Summary
Artrya Limited reported a substantial increase in net loss to $10.743 million for the half-year ended 31 December 2025, attributing the loss primarily to increased operating activities and share-based payments. Despite this, the company's net tangible assets per ordinary security saw a marked improvement, and cash reserves significantly increased due to successful share capital issuance. Artrya's focus remains on advancing its AI-driven medical technologies, with notable progress in commercializing its Salix platform in the U.S. market. The financial report also highlighted no dividends and detailed the company's financial position, including assets and liabilities as of the end of 2025.
Key Points
  • Artrya Limited reported a loss of $10.743 million for the half-year ended 31 December 2025, a 44.4% increase in loss compared to the previous period.
  • No dividends were paid, recommended, or declared during the current or previous financial periods.
  • Net tangible assets per ordinary security increased significantly to 53.67 cents from 14.61 cents as of 30 June 2025.
  • Cash and cash equivalents increased from $11.332 million to $46.521 million by 31 December 2025.
  • The company issued additional share capital, raising $80 million and incurring capital raising costs of $4.786 million.
  • Significant share-based payments were expensed during the period, with a total of $1.052 million recognized.
  • Artrya Limited is focused on developing medical technology using artificial intelligence to identify patients at risk of coronary artery disease.
  • The company achieved commercial progress in the U.S. with foundation partners like Tanner Health and Cone Health transitioning to commercial customers.
  • Artrya's total assets amounted to $92.192 million and total liabilities were $2.843 million as of 31 December 2025.
  • The interim financial report was authorized for issue by the Board of Directors on 25 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.